Entrada Therapeutics appoints Gina Chapman to board effective Sept 1, 2023

Entrada Therapeutics, Inc.

Gina Chapman, President and CEO of CARGO Therapeutics, joins as Class III director.
Effective Sept 1, 2023; also appointed to Nominating and Corporate Governance Committee.
Initial equity grant of $500K value (32,000 shares of common stock) vesting over 3 years.
Annual director fee of $40,000 plus $4,000 for committee service; standard indemnification.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Gina Chapman

Class III director

TRDA · Entrada Therapeutics, Inc.

Effective: 2023-09-01
Filed: August 10, 2023, 7:59 PM ET

On August 4, 2023, the Board of Directors (the “Board”) of Entrada Therapeutics, Inc. (the “Company”) appointed Gina Chapman to the Board as a Class III director, effective September 1, 2023

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Gina Chapman was appointed as Class III director at Entrada Therapeutics, Inc..

Action: appointed
Role: Class III director

Exact text from the filing

On August 4, 2023, the Board of Directors (the “Board”) of Entrada Therapeutics, Inc. (the “Company”) appointed Gina Chapman to the Board as a Class III director, effective September 1, 2023

View on SEC.gov

Entrada Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-089549

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.